caa a22 4500 551316578 CHVBK 20181219042044.0 cr unu---uuuuu 181213e20181126xx s 000 0 eng 10.1021/acssensors.8b00523 doi (SERVAL)BIB_03777D375057 30339020 pmid 000451495700012 isiid Two-Dimensional Label-Free Affinity Analysis of Tumor-Specific CD8 T Cells with a Biomimetic Plasmonic Sensor [Elektronische Daten] [M. Soler, X. Li, A. John-Herpin, J. Schmidt, G. Coukos, H. Altug] The screening and analysis of T cells functional avidity for specific tumor-associated antigens is crucial for the development of personalized immunotherapies against cancer. The affinity and kinetics of a T cell receptor (TCR) binding to the peptide-major histocompatibility complex (pMHC), expressed on tumor or antigen-presenting cells, have shown major implications in T cell activation and effector functions. We introduce an innovative methodology for the two-dimensional affinity analysis of TCR-pMHC in a label-free configuration by employing a multiparametric Surface Plasmon Resonance biosensor (MP-SPR) functionalized with artificial cell membranes. The biomimetic scaffold created with planar lipid bilayers is able to efficiently capture the specific and intact tumor-specific T cells and monitor the formation of the immunological synapse in situ. We have achieved excellent limits of detection for in-flow cell capturing, up to 2 orders of magnitude below the current state-of-the-art for plasmonic sensing. We demonstrate the accuracy and selectivity of our sensor for the analysis of CD8 &lt;sup&gt;+&lt;/sup&gt; T cells bioengineered with TCR of incremental affinities specific for the HLA-A0201/NY-ESO-I &lt;sub&gt;157-165&lt;/sub&gt; pMHC complex. The study confirmed the significance of providing a biomimetic microenvironment, compared to the traditional molecular analysis, and showed fine agreement with previous results employing flow cytometry. Our methodology is reliable and versatile; thus, it can be applied to more sophisticated photonic and nanoplasmonic technologies for the screening of multiple cell types and boost the development of novel treatments for cancer. Soler M. aut Li X. aut John-Herpin A. aut Schmidt J. aut Coukos G. aut Altug H. aut ACS sensors 3/11(2018-11-26), 2286-2295 3:11<2286-2295 2018 3 1 article serval SERVAL 700 1- Soler M. aut SERVAL 700 1- Li X. aut SERVAL 700 1- John-Herpin A. aut SERVAL 700 1- Schmidt J. aut SERVAL 700 1- Coukos G. aut SERVAL 700 1- Altug H. aut SERVAL 773 0- ACS sensors 3/11(2018-11-26), 2286-2295 3:11<2286-2295 2018 3 BK010053 XK010053 XK010000 SERVAL SERVAL SERVAL article